Stockscreener 앱 받기
336.23
4.22%
-14.80
전일 마감가:
$351.03
열려 있는:
$355
하루 거래량:
251.38K
Relative Volume:
0.68
시가총액:
$7.33B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-13.38
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
-0.29%
1개월 성능:
+9.49%
6개월 성능:
+31.25%
1년 성능:
+47.31%
1일 변동 폭
$336.23
$355.00
1주일 범위
$334.13
$355.00
52주 변동 폭
$189.00
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
336.23 | 7.33B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals to Present at 45th Annual TD Cowen Health Care Conference - MyChesCo
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - The Manila Times
Can Madrigal's TD Cowen Conference Reveal Signal Major Clinical Progress? - StockTitan
Madrigal Pharmaceuticals (MDGL) to Release Quarterly Earnings on Wednesday - MarketBeat
Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Debt Sensibly? - Simply Wall St
Kornitzer Capital Management Inc. KS Invests $4.55 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra sales fuel stock's growth potential - Investing.com Nigeria
Madrigal Pharmaceuticals Reports Q2 2024 Financial Results and Provides Updates - MSN
(MDGL) Investment Report - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Fiera Capital Corp - MarketBeat
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN
What is Leerink Partnrs' Estimate for MDGL FY2024 Earnings? - MarketBeat
Newbridge Financial Services Group Inc. Takes $1.30 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on - EIN News
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Rheos Capital Works Inc. Cuts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - The Motley Fool
Madrigal Pharmaceuticals CEO sells shares worth $531,020 - MSN
(01/29/25) Top Picks 2025: Madrigal Pharmaceuticals (MDGL) - Moneyshow.com
Madrigal Pharmaceuticals CEO sells shares worth $531,020 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals executive sells shares worth $34,529 - MSN
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals executive sells shares worth $34,529 By Investing.com - Investing.com Canada
(MDGL) Trading Advice - Stock Traders Daily
Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Brokers Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
Cantor Fitzgerald Estimates MDGL FY2025 Earnings - Defense World
MDGL (Madrigal Pharmaceuticals) Long-Term Debt & Capital Le - GuruFocus.com
Cantor Fitzgerald Predicts MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Madrigal Pharmaceuticals Inc 주식 (MDGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO |
Jan 24 '25 |
Sale |
335.24 |
1,584 |
531,020 |
54,303 |
| Taub Rebecca | Pres., R&D, and CMO |
Jan 24 '25 |
Sale |
335.24 |
648 |
217,236 |
456,662 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. |
Jan 24 '25 |
Sale |
335.24 |
103 |
34,530 |
4,955 |
0.27%
3.05%
자본화:
|
볼륨(24시간):